Biotechnology

NerView Surgical's NerveSense™ wins FACIT's top award, spotlighting a growing ecosystem making Ontario a global leader in oncology innovation.

By emphasizing deep anatomical knowledge, Medytox aims to elevate industry standards and solidify its leadership in Asia's booming medical aesthetics market.

BrioHealth Solutions gets an FDA nod for a trial of its BrioVAD, a miniaturized heart pump designed for children with advanced heart failure.

A revolutionary organ preservation system is showing 100% graft survival in new studies, promising to expand the donor pool for children in need.

CHINAPLAS 2026 preview reveals a strategic shift to bio-materials, smart factories, and deep alignment with China's ambitious industrial roadmap.

H1 launched its Site Network Suite, an AI platform promising to slash clinical trial feasibility times and reshape how sponsors and research sites connect.

With its CMO and CSO now both recipients of the AHA's top honor, Cardiovascular Clinical Sciences signals a rare concentration of elite expertise.

A new non-viral gene therapy targeting iron buildup in the eye has completed its Phase I trial, offering a potential new path for millions with dry AMD.

A novel RNA vaccine targeting hidden cancer antigens gets UK approval for a clinical trial, offering new hope for patients with hard-to-treat ovarian cancer.

ENA Respiratory appoints GSK veteran Melissa Faris to its board, a strategic move signaling an accelerated push for its innovative virus-agnostic nasal spray.

Canadian giant Apotex acquires Cumberland's U.S. branded drugs for $100M, a move that expands its hospital presence and pivots Cumberland to a biotech.

Backed by military funding, a novel protein therapy that actively grows bone has finished a key clinical trial, promising to revolutionize dental surgery.

Korean brand Dr. Reju-All's pharmacist-led approach and PDRN science captivated nearly 5,000 dermatologists, signaling a new wave in U.S. skincare.

A new T-cell therapy, RPTR-1-201, enters clinical trials, offering hope for hard-to-treat solid tumors by targeting a shared, multi-cancer marker.

RIMAN rallies 2,000 in Macau, unveiling a $3M bio-material and a bold strategy to dominate the competitive APAC K-beauty direct selling market.

TGA approves Minjuvi, a dual-targeted immunotherapy for relapsed follicular lymphoma, offering a breakthrough option beyond traditional chemotherapy.

After nine years of success, a renewed pact between Novonesis and Biocodex aims to dominate the booming global probiotics market. Here's what it means.

The life sciences advisory firm adds a heavy-hitter with $150B+ in deal experience, signaling ambitious growth and a new focus on the Southeast.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

Breakthrough trial data shows a new device can keep donor hearts viable for longer, potentially expanding the organ pool and saving thousands on waitlists.